Yesterday
Di Pilla’s HMC Capital is elbows-first with Healthscope proposal
It is understood the approach was made directly to Brookfield, and it remains to be seen if it will pass muster with Healthscope’s lenders.
This Month
The clinical trial result from hell has biotech investors on edge
From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea. Now they risk being wiped out.
Foreign investors banned: What else is in it for you
From a ban on foreign investors buying existing houses to pork-barrelling road projects in marginal electorates, here’s a sector breakdown of the budget.
Healthscope woes hurt investors after landlord pulls distribution
Rental breach notices issued to Healthscope have triggered a chain of events which have ultimately led to the operator saying it would put itself up for sale.
Investors fret over clinical trial failure’s hit on Regal funds
Phil King’s investment firm was the largest shareholder in Opthea, the eye treatment play that could become insolvent after a poor medical result.
The healthcare policies rising at more than double the average
Many Australians and scaling down their private health insurance because of the cost, which is helping to drive premium increases to between 7 and 9 per cent.
Why US drug giants are so angry about Australia’s PBS
US pharmaceutical giants hope the protectionist Trump administration will force Australia to increase the price it pays for their drugs.
Dutton promises to match Labor’s $25 prescription drugs pledge
The opposition has moved swiftly to match the government’s commitment to cut the cost of medicines by $6.60 per script.
Albanese pledges cheaper medicines with $25 scripts
Labor will pledge to cut subsidised prescription medicines by more than 25 per cent as it seeks to bolster its health credentials ahead of an election.
BGH Capital in turnaround mode at Virtus Health; opportunistic funds lurk
Sources said BGH Capital has tipped $100 million in fresh equity into Virtus over the past year to reduce leverage and fund expansion.
Game on! Healthscope’s Japanese lender sells debt; eyes on HMC Capital
Sources say SMBC’s slice of the loans has been bought by Deutsche Bank, which has traditionally worked for David Di Pilla’s HMC Capital.
Doctor fees to be laid bare under comparison site upgrade
Labor says patients will be able to check average specialist fees and out-of-pocket costs under an upgrade to the failed Medical Costs Finder website.
OneVentures-backed artificial heart start-up rattles the tin for $100m
BiVACOR has made the world’s first titanium heart and is hoping to manufacture the device commercially in Australia and the US within three years.
The AI surge: 175 new data centres and $26b in investment
The number of devices connected to the internet in each household is expected to double by 2030, fuelling a big rollout in data centres.
Barwon raises $150m for healthcare real estate
With a diverse mix of labs, clinics and hospitals, the Barwon fund’s portfolio is carefully set up to weather challenges in the healthcare sector.
David Williams says he makes no apologies for ‘aggressive’ style
The outspoken investment banker is the chairman of PolyNovo. The burns treatment company’s chief executive is leaving after a falling out with the board.
Healthscope preparing for potential sale after reaching lender deal
The Brookfield-owned private health operator says it is preparing for a potential sale of the business as part of options being explored with its lenders.
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can be up to $460 a month.
Ramsay, Healthscope reject ‘nonsense’ health insurance funding promise
The country’s biggest private hospital operators will push the government to force an increase in the percentage of their premiums paid to them.
Insurers propose rescue package to end hospital payment feud
Health insurers are offering hospitals immediate funding relief but only if the government agrees to make medical devices cheaper.